An insulin pen is a device for delivering insulin. The injection pens include an insulin cartridge, a dial to measure dosage, and a disposable needle. It allows delivery of insulin in a more accurate, simple and convenient way as compared to the vial and syringe method and thus has gain popularity.
The global diabetes injection pen market report has been segmented on the basis of product type, usage, distribution channel, and region. Increasing number of cases of diabetics is major factor expected to drive the market growth over the forecast period. Furthermore, increasing number of approval and subsequent launch of the product by players in the market is expected to propel the market growth over the forecast period. Favorable reimbursement scenario in developed countries is expected to boost the market growth.
Based on usage, the market is segmented based on disposable injection pen, reusable injection pen. The disposable diabetes injection pen segment is expected to witness rapid growth rate over the forecast period as it can be entirely thrown away after the use which in turn reduces the possibility of infection.
Based on region, the global diabetes injection pen market is segmented into North America, Europe, Latin America, Asia Pacific and Middle East and Africa. North America contributes major market share and expected to maintain its dominance over the forecast period. Asia Pacific is expected to witness rapid growth rate over the forecast period. This is attributed to the increasing prevalence of diabetes, and improving healthcare infrastructure. In addition, increasing demand of injection pen for treatment of diabetes in China and India is excepted to fuel the market growth.
Do Inquiry of the Report Here: https://marketresearch.biz/report/diabetes-injection-pen-market/#inquiry
Some prominent players in the global diabetes injection pen market are Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, Merck & Company, Inc., Astrazeneca plc, Jiangsu Delfu medical device Co., Ltd., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Biocon, and Wockhardt Ltd.